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Abstract: Chronic obstructive pulmonary disease (COPD), a respiratory disease characterized 
by a progressive decline in lung function, is considered to be a leading cause of morbidity and 
mortality. Long-acting inhaled bronchodilators, such as long-acting β
2
 agonists (LABAs) or 
long-acting muscarinic antagonists (LAMAs), are the cornerstone of maintenance therapy 
for patients with moderate-to-very-severe COPD. For patients not sufficiently controlled on 
a single long-acting bronchodilator, a combination of different bronchodilators has shown a 
significant increase in lung function. Tiotropium, a once-daily dosing LAMA, demonstrated 
sustained improvements in lung function as well as improved health-related quality of life, 
reduced exacerbations, and increased survival without altering the rate of decline in the mean 
forced expiratory volume in 1 second (FEV
1
) with fairly tolerable side effects. Olodaterol is a 
once-daily dosing LABA that has proven to be effective in improving lung function, reducing 
rescue medication use, and improving dyspnea and health-related quality of life, as well as 
improving exercise endurance with an acceptable safety profile. The combination of olodaterol 
and tiotropium provided additional improvements in lung function greater than monotherapy 
with each drug alone. Several well-designed randomized trials confirmed that the synergistic 
effect of both drugs in combination was able to improve lung function and health-related 
quality of life without a significant increase in adverse effects. The objective of this paper is 
to review available evidence on the clinical efficacy and safety of tiotropium, olodaterol, and 
their combination in patients with COPD.
Keywords: chronic obstructive pulmonary disease, bronchodilators, long-acting β
2
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Introduction
Chronic obstructive pulmonary disease (COPD) is a progressive yet controllable 
disease characterized by persistent airway obstruction triggered by an inflammatory 
response to several noxious stimuli, mainly cigarette smoke.1 The chronic inflam-
matory response may eventually stimulate the development of parenchymal tissue 
destruction (emphysema) and chronic bronchitis, which in turn contribute to most of 
the symptoms of the disease, mainly dyspnea and chronic cough.1,2
COPD is a leading cause of morbidity and mortality, with data supporting future 
predictions of it becoming the third leading cause of death, resulting in a substantial 
and increasing worldwide economic and social burden mainly driven by disease 
exacerbations and hospitalizations.1,2
As a result, management of COPD is primarily aimed at relieving and reducing 
symptoms as well as reducing the risk of future exacerbations.1,2
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So far, no treatment has been shown to improve the 
decline in lung function that happens with time; however, 
appropriate pharmacologic and nonpharmacologic interven-
tions can reduce disease-related symptoms, decrease the 
frequency and severity of exacerbations, and improve health 
status and exercise tolerance.1,2
The Global Initiative for Chronic Obstructive Lung 
Disease 2015 guidelines and other international guidelines 
shed light on three main classes of medications commonly 
used in treating COPD referred to as bronchodilators, corti-
costeroids, and methylxanthines. Inhaled therapy is preferred, 
and long-acting agents are convenient and more effective than 
short-acting ones.1–3 A stepwise approach is often implemented 
starting with short-acting bronchodilators on an “as needed” 
basis due to their rapid onset of action, then incorporating 
long-acting bronchodilators as the backbone of maintenance 
treatment, and eventually incorporating corticosteroids as 
patient symptoms and disease severity progress.1–3
Long-acting bronchodilators have even managed to 
demonstrate an acute improvement in several key respira-
tory parameters. A study by Santus et al4 was able to show 
that tiotropium was able to significantly improve inspira-
tory capacity (IC) and thoracic gas volume (TGV) after 
30–120 minutes of acute administration more than the com-
bination of budesonide/formoterol, while changes in residual 
volume were not significant. This documentation of the acute 
effects of long-acting bronchodilators is an important finding 
that demonstrates their potential role in the acute setting as 
well as in improving patient symptoms and quality of life in 
the long term. Tiotropium was able to additionally improve 
static and dynamic lung hyperinflation, exertional dyspnea 
(during activities of daily living and exertion), and exercise 
tolerance compared with placebo in several randomized, 
double-blind studies.4
When it comes to patients not adequately controlled on 
a single long-acting bronchodilator, a combination of bron-
chodilators with different mechanisms of action, such as the 
combination of a long-acting β
2
 agonist (LABA; formoterol) 
and a long-acting anticholinergic agent (tiotropium), has 
shown a significant increase in lung function translated as 
an improvement in forced expiratory volume in 1 second 
(FEV
1
) than either drug alone.5,6 A double-blind, double-
dummy, crossover, randomized study carried out by Caz-
zola et al7 to explore the acute effects of adding salmeterol 
to tiotropium in patients with stable COPD showed that the 
addition of salmeterol to tiotropium elicited a significantly 
faster onset of action and showed a trend for a greater maxi-
mum bronchodilation than single drugs alone. In two ran-
domized, double-blind, parallel-group, multicenter  studies, 
the combination of tiotropium bromide plus budesonide/
formoterol and tiotropium plus salmeterol/fluticasone 
improved trough FEV
1
 to a significantly greater extent than 
with tiotropium bromide plus placebo with a significantly 
lower rate of severe exacerbations (rate ratio [RR], 0.38; 
95% confidence interval [CI], 0.25–0.57), hospitalizations, 
or emergency room visits (RR, 0.35; 95% CI, 0.16–0.78).8 
This combination additionally managed to improve lung 
function (P=0.049), quality of life (P=0.01), and hospital-
ization rates (incidence RR, 0.53; CI, 0.33–0.86) in patients 
with moderate-to-severe COPD compared to those receiving 
tiotropium plus placebo.9
Consequently, tiotropium, marketed under the brand 
name Spiriva® HandiHaler® (Boehringer Ingelheim GmbH, 
Ingelheim, Germany) in the US, became one of the most com-
monly used once-daily bronchodilators after having proven 
efficacy in improving lung function and quality of life, and 
in reducing acute exacerbations and hospitalizations.9–11
In recent years, development of newer bronchodilators 
focused on once-daily agents since patient adherence in 
COPD has always been of concern due to its low rates and 
significant impact on patient morbidity, mortality, and quality 
of life.12 As a result, the newest addition to the once-daily 
dosing profile is the LABA olodaterol. Olodaterol is mar-
keted under the brand name Striverdi® Respimat® Inhalation 
Spray (Boehringer Ingelheim GmbH). It is approved for the 
long-term maintenance treatment of airflow obstruction in 
patients with COPD, including chronic bronchitis and/or 
emphysema.13
On August 19, 2014, after olodaterol demonstrated 
24-hour bronchodilation efficacy in several clinical stud-
ies, Boehringer Ingelheim filed a New Drug Application 
(NDA) for the fixed-dose combination (FDC) of tiotropium 
and olodaterol under the brand name Stiolto™ Respimat® 
delivered via the Respimat® Soft Mist™ inhaler (Boehringer 
Ingelheim GmbH). The NDA was accepted for review by 
the US Food and Drug administration (FDA).14 On May 21, 
2015, the FDA approved once-daily Stiolto™ Respimat® 
(tiotropium bromide and olodaterol) Inhalation Spray. It has 
been approved as a long-term, once-daily maintenance treat-
ment of airflow obstruction in patients with COPD, including 
chronic bronchitis and/or emphysema. Stiolto™ Respimat® is 
not indicated to treat asthma or acute deterioration of COPD 
and it does not replace the use of a rescue inhaler.15,16
The proposed efficacy and safety of the tiotropium plus 
olodaterol FDC was demonstrated in three global Phase III 
trials: the TONADO®, VIVACITO®, and ANTHELTO® 
trials. These studies are part of a large Phase III clinical trial 
program (TOviTO®) for tiotropium plus olodaterol FDC, 
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which includes more than 8,000 people living with COPD 
worldwide.14
The primary objective of this article is to review available 
evidence on the clinical efficacy and safety of tiotropium, 
olodaterol, and their combination in patients with COPD.
Methods for selection and 
assessment of the literature
PubMed (2003–2015) was searched for primary literature 
and review articles on tiotropium, olodaterol, or the com-
bination. Mainly, clinical trials about the monocomponents 
and their combination were identified, in addition to reviews, 
meta-analysis, case reports, and guidelines for COPD. The 
search was limited to human studies published in the English 
language and included both safety and efficacy outcomes. 
Manufacturing data and product labeling were also used.
Pharmacodynamic and pharmacokinetic 
properties
Tiotropium
Mechanism of action
The anticholinergic agent tiotropium bromide is a long-
acting, potent, specific, muscarinic receptor antagonist 
with high affinity to M3 receptors located in bronchial lung 
tissue. Tiotropium bromide competitively and reversibly 
antagonizes M3 receptors, resulting in the relaxation of 
bronchial smooth muscle and subsequent bronchodilation.11,17 
It dissociates slowly from M3 receptors, giving a 24-hour 
bronchodilator effect. Tiotropium also increases expiratory 
airflow, decreases smooth muscle tone in the airways, and 
consequently reduces lung hyperinflation, which in turn 
improves exercise endurance.17 Another potential mechanism 
by which tiotropium contributes to improved lung hyperinfla-
tion is its effect on airway inflammation and the production 
of reactive oxidative species. A study performed by Santus 
et al,18 in which 24 COPD patients were randomized to 
receive either formoterol (12 μg twice a day) or tiotropium 
(18 μg once daily), showed a better anti-inflammatory activ-
ity profile with tiotropium when compared to formoterol in 
a clinical setting, reducing superoxide and leukotriene B
4
 
(LTB
4
) production by peripheral neutrophils.
Dosing and pharmacokinetics
Tiotropium bromide inhalation powder is approved at a dose 
of 18 μg once daily. Following inhalation of tiotropium bro-
mide in healthy, young volunteers, 19.5% of the dose reaches 
the lungs with a C
max
 achieved almost 5 minutes after inhala-
tion. The pharmacokinetics of the drug are slightly altered 
in patients with COPD in which 14% of the delivered dose 
is excreted in the urine, with the remainder being deposited 
in the gastrointestinal tract and eliminated in the feces. No 
dosage adjustment is required in the elderly or in patients 
with hepatic impairment; however, use should be monitored 
closely in patients with moderate-to-severe renal impairment 
(creatinine clearance of #50 mL/min).17–20
Adverse drug reactions and drug interactions
Avoid coadministration with other anticholinergic drugs. 
The most common adverse reactions reported in clinical trials 
were dry mouth, sinusitis, pharyngitis, nonspecific chest pain, 
and upper respiratory and urinary tract infections.17–20 Further 
reported adverse reactions from a 4-year trial were headache, 
constipation, depression, insomnia, and arthralgia.20
Contraindications and precautions
Use is contraindicated in patients with a history of hypersen-
sitivity to tiotropium, ipratropium (atropine derivatives), or 
any components of Spiriva capsules. Caution in patients with 
severe hypersensitivity to milk proteins and patients with a 
history of hypersensitivity reactions to atropine should be 
closely monitored for cross-reactions. Use with caution in 
patients with narrow-angle glaucoma or urinary retention 
due to risk of symptom worsening.17–20
Olodaterol
Mechanism of action
Olodaterol is a potent and selective β
2
-adrenergic receptor 
agonist. By binding and activating β
2
-adrenergic receptors in 
the airways, olodaterol mediates intracellular adenyl cyclase 
stimulation, with a consequent increase in cyclic adenosine 
monophosphate levels, which relaxes the smooth muscles 
of the airways to achieve bronchodilation. It forms a stable 
complex with the β
2
-adrenergic receptor, with a dissociation 
half life of 17.8 hours. Single doses of olodaterol improved 
FEV
1
 for 24 hours in patients with COPD.13,21
Dosing and pharmacokinetics
The recommended dosage of olodaterol is 5 μg inhaled once 
daily (as two actuations) via the Respimat soft mist inhaler. 
The pharmacokinetics of olodaterol follows a linear pattern, 
with systemic exposure to the drug increasing in proportion 
to dose. After inhaled administration, maximum plasma 
concentrations of olodaterol are generally achieved within 
10–20 minutes, and the estimated absolute bioavailability of 
the drug is approximately 30%. The dosage of olodaterol does 
not require adjustment in patients with renal impairment or 
those with mild or moderate hepatic impairment.17 Important 
pharmacokinetic information on tiotropium and olodaterol 
is listed in Table 1.11,13
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Adverse drug reactions and drug interactions
The most frequent adverse reactions with olodaterol included 
nasopharyngitis, bronchitis, back pain, upper respiratory 
and urinary tract infections, rash, and arthralgia.13 The most 
common adverse reactions with the combination Stiolto™ 
Respimat® (3% incidence and higher than any of the 
comparators – tiotropium and/or olodaterol) were nasophar-
yngitis, 12.4% (11.7%/12.6%), cough, 3.9% (4.4%/3.0%), 
and back pain, 3.6% (1.8%/3.4%).15
Drugs known to prolong the QT interval, such as monoamine 
oxidase inhibitors and tricyclic antidepressants, may potentiate 
the cardiovascular (CV) effects of olodaterol, and ketoconazole 
may increase systemic exposure to it; thus, caution is advised 
when coadministering olodaterol with these agents.13,22 More-
over, use caution if administering adrenergic drugs because sym-
pathetic effects of olodaterol may be potentiated. Concomitant 
treatment with xanthine derivatives, steroids, or diuretics may 
potentiate the hypokalemic effect of olodaterol.22
Contraindications and precautions
Olodaterol requires caution in several patient populations, 
including those with CV disorders, QT interval prolongation, 
thyrotoxicosis, convulsive disorders, or sensitivity to sym-
pathomimetic amines, and should not be used for the treat-
ment of acute COPD symptoms, acute COPD deterioration, 
or asthma.13,22,23 Table 2 summarizes some precautions that 
should be taken into consideration when using tiotropium or 
olodaterol in special populations.
Dosing of the combination Stiolto™ Respimat®
Each actuation from the mouthpiece of the newly approved 
combination contains 3.124 μg tiotropium bromide mono-
hydrate, equivalent to 2.5 μg tiotropium, and 2.736 μg 
olodaterol hydrochloride, equivalent to 2.5 μg olodaterol. 
Stiolto™ Respimat® should be administered as two oral 
inhalations once-daily at the same time of the day.24
Clinical trials
Tiotropium
Tiotropium bromide has demonstrated significant improve-
ments in patients’ health-related quality of life and has 
managed to reduce the number of acute exacerbations and 
hospitalizations, in addition to improving dyspnea, and 
reducing adverse events (AEs) compared to placebo. Several 
well-designed studies comparing tiotropium to placebo and 
to the most commonly used LABAs (salmeterol, formoterol, 
and indacaterol) over periods ranging from 3 to 48 months 
of follow-up provided solid evidence that tiotropium was at 
least as safe and effective if not superior to other long-acting 
bronchodilators.25
One of the landmark trials comparing the safety and 
efficacy of tiotropium to placebo was the 4-year UPLIFT 
(Understanding Potential Long-term Impacts on Function 
with Tiotropium) trial in which tiotropium was able to provide 
sustained improvements in lung function and health-related 
quality of life in patients with moderate-to-very-severe COPD 
with a significant change in the St George’s Respiratory 
Table 1 Pharmacokinetics of tiotropium and olodaterol
Absorption Distribution Metabolism Elimination
Tiotropium Tmax 5 minutes
Bioavailability 19.5% (inhalation)
72% bound to 
plasma proteins
Hepatic (minimal), via CYP2D6 
and CYP3A4
excretion: urine (16%); feces 
(primarily nonabsorbed drug)
Olodaterol Tmax 10–20 minutes
Bioavailability 30% (inhalation)
60% bound to 
plasma proteins
Direct glucuronidation (UGT2B7, UGT1A1, 
1A7, and 1A9) and O-demethylation 
(primarily CYP2C9 and 2C8)
excretion: urine (9% 
unchanged); majority in feces
Abbreviations: Tmax, time to peak plasma concentration; CYP, cytochrome P450.
Table 2 Special populations and Stiolto™ respimat
Special populations Comments
Pediatric (aged ,18 years) Safety and efficacy of olodaterol and tiotropium has not been established in this population
Geriatric population Tiotropium: monitoring patients with moderate-to-severe renal impairment due to increased plasma drug levels
Olodaterol: no differences in effectiveness or adverse effects were noted in geriatric patients compared 
to younger adults
Pregnancy/lactation Pregnancy category C
excretion in breast milk unknown/use caution
Renal impairment Tiotropium: caution in moderate-to-severe renal impairment; monitor closely
Olodaterol: no dosage adjustment necessary
Hepatic impairment No dosage adjustment necessary for both tiotropium and olodaterol
Notes: Pregnancy category C: animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans.
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Questionnaire (SGRQ) total score (ranging from 2.3 to 3.3 
units, P,0.001). Tiotropium was also able to reduce exacerba-
tions and associated hospitalizations with a significant delay 
in the time to the first exacerbation of 16.7 months (95% CI, 
14.9–17.9) versus 12.5 months (95% CI, 11.5–13.8) in the pla-
cebo group. Furthermore, tiotropium was able to demonstrate 
an increased survival without altering the rate of decline in the 
mean FEV
1
 compared to placebo, and it was associated with a 
reduction in the risk of CV mortality and CV events.26,27
Bateman et al28 evaluated the long-term efficacy and 
safety of tiotropium 5 or 10 μg versus placebo, inhaled via 
the Respimat® Soft Mist™ Inhaler (SMI) in two multicenter, 
multinational, randomized, double-blind, parallel-group 
1-year studies involving 1,990 patients. The two studies 
were combined and had four coprimary endpoints (trough 
FEV
1 
response, Mahler transition dyspnea index [TDI] 
and SGRQ scores all at week 48, and COPD exacerba-
tions per patient-year). The mean trough FEV
1 
response 
of tiotropium 5 or 10 μg relative to placebo was 127 or 
150 mL, respectively (both P,0.0001). The COPD exac-
erbation rate was significantly lower with tiotropium 5 μg 
(RR =0.78; P=0.002) and tiotropium 10 μg (RR =0.73; 
P=0.0008); the health-related quality of life and Mahler 
TDI coprimary endpoints were significantly improved with 
both doses (both P,0.0001). Tiotropium Respimat® SMI 
5 μg demonstrated sustained improvements in patients 
with COPD relative to placebo and similar to the 10 μg 
dose but with a lower frequency of anticholinergic AEs.28 
In trials involving the comparison of tiotropium to other 
active treatments such as salmeterol, tiotropium bromide 
was able to significantly lower the rate of exacerbations 
and delay the time to first exacerbation.25 However, exac-
erbation rates did not significantly differ between patients 
receiving tiotropium bromide and those receiving the FDC 
of salmeterol/fluticasone propionate (RR, 0.967; 95% CI, 
0.836–1.119; P=0.656).9,29
Moreover, pooled data from several randomized con-
trolled trials comparing tiotropium to salmeterol found that 
tiotropium was superior in improving quality of life as mea-
sured by the SGRQ, with a significant improvement in FEV
1
 
from baseline as well as marked improvements in dyspnea 
and rescue medication use.30–32
Compared to formoterol, a 6-week study done by van 
Noord et al6 revealed that tiotropium resulted in a signifi-
cantly greater improvement in FEV
1
 (127 vs 86 mL). The 
combination of tiotropium plus formoterol was superior in 
improving FEV
1
 compared to each drug alone (234 mL), with 
an accompanying significant decrease in daytime salbutamol 
use during combination therapy.7 In few of the short-term 
studies that evaluated the efficacy of indacaterol compared 
to tiotropium, the LABA was comparable to tiotropium in 
improving health-related outcomes.33,34
Findings from several studies have consistently reported 
that tiotropium is safe and well tolerated, with the most 
commonly reported AE being dry mouth.35,36 However, 
the debate still remains around the safety of the Respimat 
inhaler compared to the Handihaler delivery device, with the 
former being associated with an increased risk of mortality. 
A pooled analysis of two 30-week, double-blind, double-
dummy, crossover studies, involving 207 COPD patients, 
both tiotropium doses (5 or 10 μg) delivered by Respimat 
SMI were significantly superior to placebo and noninferior 
to tiotropium 18 μg HandiHaler on the primary endpoint 
of (FEV
1
) response (all P,0.0001). All active treatments 
were significantly superior to placebo (all P,0.0001) and 
both doses of tiotropium Respimat SMI were noninferior to 
tiotropium 18 μg HandiHaler on the secondary spirometry 
variables and rescue medication use.37
A recent trial of over 17,000 patients concluded that 
tiotropium 2.5 or 5 μg delivered via Respimat had a similar 
safety profile and exacerbation efficacy to that of tiotropium 
18 μg delivered via Handihaler, in terms of similar rates of 
death, major CV AEs, and risk of first exacerbation.38,39
Olodaterol
Olodaterol is a novel long-acting inhaled β
2 
adrenergic 
receptor agonist approved for the long-term, once-daily 
maintenance treatment of airflow obstruction in patients with 
COPD. It has demonstrated efficacy in several randomized, 
well-designed clinical trials ranging across a period of 6–48 
weeks.
In four pivotal, 48-week, Phase III trials, the addition 
of olodaterol 5 μg once daily to usual maintenance therapy 
significantly (P,0.05) improved lung function compared with 
the addition of placebo. Significant (P,0.05) improvements 
in FEV
1
 area under the curve (AUC)
0–3
 and trough FEV
1
 were 
maintained throughout 48 weeks in all four trials.40,41 In two 
of these trials, treatment with olodaterol or formoterol for 24 
weeks was not associated with significant improvements rela-
tive to placebo in terms of the coprimary endpoint of the TDI 
focal score. However, a significantly greater improvement 
with olodaterol than with placebo in the key secondary end-
point of SGRQ was seen as well as a reduced need for daytime 
and night-time rescue medication relative to placebo.41
International Journal of COPD 2015:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2352
Ramadan et al
The FEV
1
 AUC profile over 24 hours was significantly 
(P,0.001) better with olodaterol than with placebo and was 
generally similar to that of tiotropium 18 μg once daily in a 
6-week Phase III trial.42 Findings from a 4-week trial demon-
strated significant (P,0.0001) improvement in trough FEV
1
 
with olodaterol in Japanese patients with COPD.43 Olodaterol 
treatment also significantly improved exercise endurance 
time (ET) by 11.8% and 14% (P#0.0018).44
Several 48-week trials evaluating the safety profile of 
olodaterol in adults with moderate to severe COPD have been 
conducted. Results concluded that olodaterol 5 or 10 μg is 
generally well tolerated with a comparable safety profile to 
formoterol and placebo, with the most common AEs being 
nasopharyngitis, upper respiratory tract infection, cough, 
COPD exac erbation, and pneumonia. The most frequent type 
of serious AEs observed was lung cancer, with a higher inci-
dence in patients receiving olodaterol 10 μg, formoterol, and 
placebo compared to those receiving olodaterol 5 μg.13,40,41,45
Tiotropium/olodaterol FDC
With the goal of improving patient outcomes and adherence, 
a number of once- or twice-daily fixed-dose long-acting 
muscarinic antagonist (LAMA)/LABA combinations are 
under development, with the most recently approved being 
the Boehringer Ingelheim treatment consisting of the FDC of 
tiotropium and olodaterol. There is growing research and evi-
dence suggesting that combining a fixed dose of a β
2
-agonist 
and a muscarinic antagonist achieves better bronchodilation 
and clinical outcomes compared with either agent alone. With 
a once-daily dosing profile, they are anticipated to impact 
favorably on patient preference and compliance. This com-
bination provides an effective, convenient, and potentially 
safer alternative to a LABA/ICS combination. The new 
formulation delivered as oral inhalation via the Respimat® 
inhaler overcomes some of the limitations of metered dose 
inhalers, such as hand-breath coordination and generation of 
high inspiratory flow.46
Encouraging data from preclinical models with tiotro-
pium plus olodaterol demonstrated synergistic effects on 
bronchoprotection in vivo, which lead to replicated positive 
results in Phase II and III clinical trials.47
Clinical Phase II trials aimed at finding the optimal dose 
for the combination of tiotropium/olodaterol.48,49 All combi-
nations of tiotropium/olodaterol demonstrated higher FEV
1
 
and FVC values than the respective tiotropium or olodaterol 
monotherapy with the following P-values: tiotropium/
olodaterol 5/2 μg (P=0.008), 5/5 μg (P=0.012), and 5/10 μg 
(P,0.0001).48,49
Several well-designed, randomized, global Phase III trials 
evaluated the effect of the combination of olodaterol and 
tiotropium on lung function and exercise endurance versus 
placebo and/or their individual components. The results of 
these trials are summarized in Table 3. The 52-week replicate 
TONADO 1 and 2 studies enrolled more than 5,500 patients 
with moderate-to-very-severe COPD. Results showed that 
lung function, as measured by FEV
1
 AUC
0–3
 and trough 
FEV
1
 response, significantly improved in patients receiving 
tiotropium plus olodaterol FDC 2.5/5 or 5/5 μg delivered 
via the Respimat® inhaler versus the monocomponents in 
both studies (P,0.0001 for all comparisons). Sustained 
improvements in trough FEV
1
 responses were seen after 
24 weeks of treatment with tiotropium plus olodaterol FDC 
2.5/5 μg, 5/5 μg compared to tiotropium 2.5, 5, and olodat-
erol 5 μg with the following values 111, 136, 83, 65, and 
54 mL, respectively. Statistically significant improvement 
was seen with the combination versus the individual compo-
nents at 24 weeks (P,0.05 for all comparisons).50 A subgroup 
analysis of FEV
1
 AUC
0–3
 and trough FEV
1
 stratified accord-
ing to inhaled corticosteroid use showed that tiotropium plus 
olodaterol improved lung function irrespective of whether 
patients were receiving inhaled corticosteroids or not. After 
24 weeks, statistically significant improvements in SGRQ total 
score were seen for tiotropium plus olodaterol FDC 5/5 μg 
over corresponding individual components (versus olodaterol 
5 μg; P,0.01; versus tiotropium 5 μg; P,0.05) but not for 
tiotropium plus olodaterol FDC 2.5/5 μg versus the individual 
components.50 In addition, statistically significant improve-
ments were also observed for the secondary endpoint of the 
Mahler TDI focal score at 24 weeks for both tiotropium plus 
olodaterol FDCs versus their monocomponents (P,0.05). 
Both tiotropium plus olodaterol FDC 5/5 and 2.5/5 μg 
reduced the 24-hour rescue medication use compared to the 
monotherapy components throughout the 52-week treatment 
period. Kaplan–Meier estimates of probability of moderate/
severe COPD exacerbation showed a trend for improvement 
in exacerbations with both FDCs versus the monotherapy 
components.50
Similar results were achieved in the 6-week cross-over 
Phase III VIVACITO™ study in which once-daily tiotro-
pium plus olodaterol FDC improved lung function (FEV
1
) of 
COPD patients to levels significantly above those achieved 
with tiotropium or olodaterol monotherapies, or with placebo 
sustained over 24 hours with a side-effect profile similar to 
tiotropium monotherapy.51
Results from two replicate, double-blind, randomized, 
12-week studies (ANHELTO 1 and 2) that evaluated the 
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efficacy and safety of olodaterol 5 μg once daily (via Respimat®) 
combined with tiotropium 18 μg once daily (via HandiHaler®) 
versus tiotropium 18 μg once daily (via HandiHaler®) combined 
with placebo (via Respimat®) in patients with moderate-to-
severe COPD further reinforced the pooled data on the efficacy 
of this FDC.52 Olodaterol + tiotropium managed to significantly 
improve FEV
1
 AUC
0–3
 over tiotropium + placebo (ANHELTO 1: 
treatment differences: 0.117 L [P,0.001]; ANHELTO 2: 
0.106 L [P,0.001]) and trough FEV
1
 (ANHELTO 1: treat-
ment differences: 0.062 L [P,0.001], ANHELTO 2: 0.040 L 
[P,0.0029]). These effects translated to improvements in 
SGRQ total scores (treatment difference -1.85; P,0.0001). 
The tolerability profile of olodaterol + tiotropium was similar 
to tiotropium monotherapy.52
TORRACTO (NCT01525615) was a 12-week, double-
blind, parallel-group, placebo-controlled, Phase III study to 
evaluate the effects of tiotropium/olodaterol FDC on exercise 
endurance in patients with GOLD 2–3 COPD. A total of 
404 patients with GOLD 2–3 COPD received tiotropium 
plus olodaterol (5/5 or 2.5/5 μg) once daily via Respimat 
Soft Mist inhaler, or placebo. ET was increased, although not 
significantly, with tiotropium plus olodaterol 5/5 μg versus 
placebo at 12 weeks (21% increase, nominal P=0.06). Both 
tiotropium/olodaterol doses significantly increased pre-
exercise IC versus placebo (tiotropium plus olodaterol 5/5 μg, 
234 mL; tiotropium plus olodaterol 2.5/5 μg, 207 mL, 
nominal P,0.0005).53
Direct head-to-head trials comparing the FDC of 
tiotropium/olodaterol to other FDCs of already available 
LABAs, LAMAs, or ICS are lacking. However, the ENER-
GITO (NCT01969721) trial, which is part of the TOviTO 
program, is intended to provide evidence of superior 
improvements in lung function with high- and low-dose FDC 
of tiotropium and olodaterol (FDC1.25/2.5 and 2.5/2.5 μg) 
compared with high- and low-dose FDC of fluticasone pro-
pionate and salmeterol (Accuhaler® [GlaxoSmithKline plc, 
London, UK] 250/50 and 500/50 μg) in 228 COPD patients. 
The primary outcome is a change from baseline in FEV
1
 
AUC
0–12
.54 The study was completed in February 2015, but 
no study results are published yet.
Cost effectiveness
According to US estimates, the average wholesale price 
(AWP)/month of Striverdi® Respimat is approximately 
Table 3 Clinical trial results of tiotropium and olodaterol combination
Study Arms Efficacy endpoints Findings
TONADO 1 and 250 Tiotropium plus olodaterol 
FDC 5/5 μg or 2.5/5 μg versus 
monocomponents (olodaterol  
5 μg or Tiotropium 5 μg or  
2.5 μg) Respimat
AUC0–3 of Fev1, 
trough Fev1, and 
SGRQ total score 
over 52 weeks 
Improvements in Fev1 AUC0–3 with tiotropium plus 
olodaterol FDC 5/5 μg and 2.5/5 μg over individual 
components were SS (P,0.0001 for all comparisons)
Improvements in trough Fev1 with combination 
were SS (P,0.05 for all comparisons)
SS improvements in SGRQ for FDC 5/5 μg 
over monocomponents (versus olodaterol 
5 μg: -1.693±0.553*, P,0.01; versus tiotropium 
5 μg: -1.233±0.551*, P,0.05) but not for 
tiotropium plus olodaterol FDC 2.5/5 μg
vIvACITO51 Tiotropium plus olodaterol FDC 
(2.5/5 μg, 5/5 μg) versus tiotropium 
(2.5 μg or 5 μg) and olodaterol (5 
μg) monotherapy via Respimat
24-hour Fev1 time 
profile over 6 weeks
Significant improvement in FEV1 with the FDC 
versus monocomponents
ANTHeLTO 1 and 252 Olodaterol 5 μg once daily 
(via Respimat®) combined with 
tiotropium 18 μg once daily (via 
HandiHaler®) versus tiotropium 
18 μg once daily (via HandiHaler®) 
combined with placebo 
(via Respimat®)
AUC0–3 of Fev1, 
trough Fev1, and 
SGRQ total score 
over 12 weeks
Significant improvements with the FDC over 
tiotropium + placebo in: Fev1 AUC0–3 (treatment 
differences: 0.117 L [P,0.001], ANHeLTO 1; 
0.106 L [P,0.001], ANHeLTO 2)
Trough Fev1 (treatment differences: 0.062 L 
[P,0.001]), ANHeLTO 1; 0.040 L [P=0.0029], 
ANHeLTO 2
Improvements in SGRQ total scores (treatment 
difference -1.85; P,0.0001)
TORRACTO53 Tiotropium plus olodaterol (5/5 μg 
or 2.5/5 μg) once daily via Respimat 
Soft Mist inhaler, or placebo
exercise eT at  
12 weeks
ET significantly increased (21% increase, P=0.06)
Significantly increased pre-exercise IC (P,0.0005)
Notes: *Data are presented as adjusted mean ± standard error.
Abbreviations: ET, endurance time; FDC, fixed-dose combination; FEV1, forced expiratory volume in 1 second; IC, inspira tory capacity; SGRQ, St George’s Respi ratory 
Questionnaire; SS, statistically significant.
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$87.19 while that of Spiriva® Handihaler is $357.37.11,13 
Olodaterol appears to be more expensive than similar drugs 
of its class such as indacaterol which has an AWP/month 
of $8.08.55 However, no head-to-head trials comparing 
olodaterol to indacaterol have yet been published to prove 
if olodaterol therapy translates into better clinical outcomes 
that would justify its increased cost.
The AWP of the combination Stiolto™ Respimat®/month 
is $378.82 in the US.56 Nevertheless, no cost-estimate or 
cost-effectiveness analyses have yet been done on the com-
bination of tiotropium/olodaterol versus other combinations 
in the treatment of patients with COPD.
Formulary considerations
Patients with moderately severe COPD suffer from 
repeated hospitalizations, debilitating symptoms, and 
impaired HRQOL. As a result, they are likely to be on 
more than one bronchodilator therapy to treat airflow 
obstruction. Guidelines recommend combination therapy 
involving two long-acting bronchodilators with different 
modes of action in patients whose COPD is not sufficiently 
controlled with monotherapy. Thus, ongoing research on 
combination bronchodilators has been on the rise in an 
effort to provide new treatment options for maintenance 
treatment of COPD.57
Both olodaterol and tiotropium monotherapies are 
approved as options for long-term maintenance treatment 
of COPD on the basis of proven similar efficacy to already 
existing bronchodilators such as salmeterol, formoterol, and 
their combinations. Tiotropium managed to improve lung 
function, exercise endurance, and HRQOL in addition to its 
ability to reduce exacerbations compared to the LABAs sal-
meterol, formoterol, and indacaterol.11 Similarly, olodaterol 
demonstrated symptomatic improvements in lung function 
over 24 hours and enhanced health outcomes, as assessed 
by the SGRQ compared to tiotropium, salmeterol, and for-
moterol.13 The FDC of tiotropium plus olodaterol, approved 
by the FDA, has demonstrated sustained improvements in 
lung function, as measured by trough FEV
1
 and in SGRQ 
total score over 6–48 weeks compared to those receiving 
olodaterol or tiotropium alone.57 The FDC has an acceptable 
safety profile, with most frequent adverse effects being dry 
mouth, nasopharyngitis, bronchitis, cough, and back pain. 
This LAMA/LABA combination is the first product on the 
market that offers an alternative to dry powder delivery sys-
tems with a once-daily dosing regimen that aims at improving 
adherence especially in patients who require treatment with 
both monocomponents alone. Because of the slower spray 
velocity and longer spray duration, the use of Respimat is less 
dependent on inhalation technique. A spacer is not needed 
with Respimat. In addition, Respimat does not require gen-
eration of high inspiratory flow rates required for some dry 
powder inhalers.58 Another advantage that this combination 
offers is that it does not include a corticosteroid, which spares 
the patient from the multiple adverse effects associated with 
corticosteroids in the long term. Further longer duration trials 
against active comparators are needed to ascertain if this 
FDC offers any additional advantages over other combina-
tion inhalers with regard to efficacy, safety, and quality of 
life. This FDC’s low potential for adverse effects, ease of 
administration, and once-daily regimen may improve patient 
outcomes and adherence to therapy.
Conclusion
Tiotropium/olodaterol FDC therapy has been proven effec-
tive in several well-designed randomized controlled trials 
involving thousands of patients. It is a promising option for 
maintenance treatment of patients with COPD. Compared 
to tiotropium alone, it has shown greater improvement in 
lung function, symptom control, and HRQOL. In an effort 
to further explore the efficacy and safety of this FDC and 
as part of the extensive TOviTO® clinical trial program for 
tiotropium plus olodaterol Respimat® FDC, DYNAGITO® is 
a 52-week multinational double-blind ongoing trial designed 
to investigate the impact of once-daily, orally inhaled tiotro-
pium plus olodaterol Respimat® FDC (5/5 μg) compared to 
Spiriva Respimat® monotherapy (5 μg) on exacerbations in 
patients with severe to very severe COPD.59 The benefit of 
tiotropium plus olodaterol Respimat® FDC on survival will 
also be evaluated in this new study.51 Data from future clinical 
trials investigating this innovative combination will further 
add to the already existing pool of evidence supporting the 
effectiveness and convenience of this once-daily combina-
tion inhaler.
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